An important class of immune cells, called myeloid cells, including myeloid derived suppressor cells (MDSCs), tumor associated macrophages and immature dendritic cells (DCs), represent alternative drug target populations that accumulate in cancer and can undermine the efficacy of current cancer treatments (ref 4 and 5).